HealthET Tech34 minutes ago
Moody's, S&P boost Sun Pharma ratings
2 min read
Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries for its proposed USD 11.75-billion acquisition of US-based Organon & Co. S&P gave a 'BBB+' rating, Moody's a 'Baa1', both with a 'stable' outlook.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
